Otsuka Pharmaceuticals and Click Therapeutics announced that Rejoyn, a smartphone-based prescription digital therapeutic for major depressive disorder (MDD), scored FDA clearance to be used as an adjunct to clinician-managed care.
Rejoyn is a six-week remote treatment program to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional training...
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).
The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).
The studies, published in npj Digital Medicine, the Journal of Affective Disorders, and presented at the Society of Biological Psychiatry Annual Scientific Convention in New York, showed the therapeutic to reduce symptoms, pair well with...
